Search hospitals > New Hampshire > Concord
New Hampshire Oncology Hematology PA-Concord
Claim this profileConcord, New Hampshire 03301
Global Leader in Parotid Gland Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Breast cancer
107 reported clinical trials
1 medical researcher
Summary
New Hampshire Oncology Hematology PA-Concord is a medical facility located in Concord, New Hampshire. This center is recognized for care of Parotid Gland Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Breast cancer and other specialties. New Hampshire Oncology Hematology PA-Concord is involved with conducting 107 clinical trials across 146 conditions. There are 1 research doctors associated with this hospital, such as Douglas Weckstein, MD.Area of expertise
1Parotid Gland Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderER positive
HER2 negative
PR positive
Top PIs
Clinical Trials running at New Hampshire Oncology Hematology PA-Concord
Breast Cancer
Lung Cancer
Prostate Cancer
Non-Small Cell Lung Cancer
Breast cancer
Bladder Cancer
Parotid Gland Cancer
Prostatic Neoplasm
Rectal Cancer
Prostate Adenocarcinoma
Hormone Therapy with or without Radiation
for Breast Cancer
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Recruiting2 awards Phase 313 criteria
Low Dose Tamoxifen
for Breast Cancer
This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogens. It blocks the activity of estrogen (a female hormone) in the breast. This may stop the growth of some breast tumors that need estrogen to grow. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy to treat postmenopausal women with hormone-dependent breast cancer. Giving low dose tamoxifen may be more effective compared to usual hormone therapy in treating post-menopausal women with hormone-positive, HER2 negative early stage breast cancer.
Recruiting2 awards Phase 38 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at New Hampshire Oncology Hematology PA-Concord?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.